PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32576961-6	2020	The novel combination treatment with azacitidine and the MEK-inhibitor trametinib additively inhibited ERK-phosphorylation and thus depleted the signal from mutated NRAS.	Azacitidine	37-48	neuroblastoma ras oncogene	Mus musculus	165-169	
32576961-8	2020	Thus, we identified the combination of azacitidine and trametinib as an effective treatment in NRAS-mutated CMML and propose its clinical development.	Azacitidine	39-50	neuroblastoma ras oncogene	Mus musculus	95-99